Literature DB >> 33443677

Clinical Impact of Pathological Features Including the Ki-67 Labeling Index on Diagnosis and Prognosis of Adult and Pediatric Adrenocortical Tumors.

Sebastiao N Martins-Filho1,2, Madson Q Almeida3,4, Ibere Soares1, Alda Wakamatsu5, Venancio Avancini F Alves1,5, Maria Candida Barisson V Fragoso3,4, Maria Claudia N Zerbini6.   

Abstract

Adrenocortical tumors (ACT) in the adult and pediatric population are generally considered distinct entities due to differences in molecular events related to tumorigenesis, clinical presentation, and outcome. Furthermore, pathological criteria used for diagnosis and prognostication of ACT in adults are usually inadequate for predicting the biological behavior of ACT in children. Here, we analyzed 146 adult and 44 pediatric (< 15y/o) ACT with long-term clinical follow-up and furthered current evidence on the clinical and pathological differences between pediatric and adult tumors. Predilection for female over male gender was observed in both cohorts, but more so in adults (84% vs. 61%, p = 0.003). Cushing syndrome was more frequent in adults (p < 0.001), whereas virilization, either isolated (p < 0.001) or combined to Cushing (p = 0.047), was more common in children. The Ki67 labelling index (LI) of pediatric adenomas and carcinomas was much higher than their corresponding tumors in adults (p < 0.001). Despite these differences, pathological analyses including the evaluation of Ki67 greatly improved patient prognostication in both age cohorts. Indeed, increased Weiss scores and Ki67 indexes correlated with poor overall- and disease-free survival in adult patients with carcinoma. Among the proliferative indexes tested, Ki67 LI ≥ 10% showed the highest hazard ratio (HR) for recurrence and the Ki67 LI ≥ 3% showed the highest HR for survival. In pediatric tumors, the Wieneke score (p < 0.001) and the Ki67 LI (p < 0.001) showed high accuracy for predicting biological behavior, and increased scores/indexes correlated with worse overall and disease-free survival. In this age cohort, Ki67 LI < 10% was able to rule out malignant behavior, whereas Ki67 LI ≥ 15% may be used to predict the patients with higher risks of recurrence and/or poor outcome.

Entities:  

Keywords:  Adrenocortical tumor; Adult adrenocortical carcinoma; Automated digital analysis; Ki-67 labelling index; Pediatric adrenocortical carcinoma

Year:  2021        PMID: 33443677     DOI: 10.1007/s12022-020-09654-x

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  19 in total

Review 1.  Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults.

Authors:  André M Faria; Madson Q Almeida
Journal:  Mol Cell Endocrinol       Date:  2011-10-14       Impact factor: 4.102

Review 2.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 3.  Molecular epidemiology of adrenocortical tumors in southern Brazil.

Authors:  Gislaine Custódio; Heloisa Komechen; Francisco R O Figueiredo; Natasha D Fachin; Mara A D Pianovski; Bonald C Figueiredo
Journal:  Mol Cell Endocrinol       Date:  2011-10-25       Impact factor: 4.102

4.  Adrenocortical Carcinoma in Children: A Clinicopathological Analysis of 41 Patients at the Mayo Clinic from 1950 to 2017.

Authors:  Nidhi Gupta; Michael Rivera; Paul Novotny; Vilmarie Rodriguez; Irina Bancos; Aida Lteif
Journal:  Horm Res Paediatr       Date:  2018-05-25       Impact factor: 2.852

Review 5.  The International Pediatric Adrenocortical Tumor Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors.

Authors:  Raul C Ribeiro; Emilia M Pinto; Gerard P Zambetti; Carlos Rodriguez-Galindo
Journal:  Mol Cell Endocrinol       Date:  2011-10-23       Impact factor: 4.102

6.  Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study.

Authors:  Jarod P McAteer; Jorge A Huaco; Kenneth W Gow
Journal:  J Pediatr Surg       Date:  2013-05       Impact factor: 2.545

7.  Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors?

Authors:  Louis P Dehner; D Ashley Hill
Journal:  Pediatr Dev Pathol       Date:  2009 Jul-Aug

8.  Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry.

Authors:  E Michalkiewicz; R Sandrini; B Figueiredo; E C M Miranda; E Caran; A G Oliveira-Filho; R Marques; M A D Pianovski; L Lacerda; L M Cristofani; J Jenkins; C Rodriguez-Galindo; R C Ribeiro
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

Review 9.  Clinical review: Adrenocortical carcinoma: clinical update.

Authors:  Bruno Allolio; Martin Fassnacht
Journal:  J Clin Endocrinol Metab       Date:  2006-03-21       Impact factor: 5.958

10.  Prognostic Factors of Adrenocortical Carcinoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database

Authors:  Sen Wang; San-San Chen; Wei-Cheng Gao; Liang Bai; Li Luo; Xiang-Guang Zheng; You Luo
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26
View more
  5 in total

Review 1.  Adrenocortical carcinoma: Pediatric aspects (Review).

Authors:  Florica Sandru; Răzvan-Cosmin Petca; Mara Carsote; Aida Petca; Mihai Cristian Dumitrascu; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2022-02-16       Impact factor: 2.447

2.  Prognosis and Therapeutic Efficacy Prediction of Adrenocortical Carcinoma Based on a Necroptosis-Associated Gene Signature.

Authors:  Dan Ji; Rongfang Zhong; Song Fan
Journal:  Biomed Res Int       Date:  2022-05-19       Impact factor: 3.246

Review 3.  Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.

Authors:  Ozgur Mete; Lori A Erickson; C Christofer Juhlin; Ronald R de Krijger; Hironobu Sasano; Marco Volante; Mauro G Papotti
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 4.056

Review 4.  EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity.

Authors:  Rebecca V Steenaard; Marieke Rutjens; Madeleine H T Ettaieb; Max M van Noesel; Harm R Haak
Journal:  Discov Oncol       Date:  2022-04-18

5.  Prenatal presentation of an adrenocortical tumor.

Authors:  Jeffrey H Schwartz; Erlyn Smith
Journal:  Cancer Rep (Hoboken)       Date:  2022-09-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.